key: cord-1049065-mero61ia
authors: Oladipo, Elijah Kolawole; Ajayi, Ayodeji Folorunsho; Ariyo, Olumuyiwa Elijah; Onile, Samson Olugbenga; Jimah, Esther Moradeyo; Ezediuno, Odinakaose Louis; Adebayo, Oluwadunsin Iyanuoluwa; Adebayo, Emmanuel Tayo; Odeyemi, Aduragbemi Noah; Oyeleke, Marvellous Oluwaseun; Oyewole, Moyosoluwa Precious; Oguntomi, Ayomide Samuel; Akindiya, Olawumi Elizabeth; Olamoyegun, Bunmi Olayemi; Aremu, Victoria Oyetayo; Arowosaye, Abiola O.; Aboderin, Dorcas Olubunmi; Bello, B. Habibat; Senbadejo, Y. Tosin; Awoyelu, Elukunbi Hilda; Oladipo, Adio Abayomi; Oladipo, Bukola Bisola; Ajayi, Lydia Oluwatoyin; Majolagbe, Olusola Nathaniel; Oyawoye, Olubukola Monisola; Oloke, Julius Kola
title: EXPLORING SURFACE GLYCOPROTEIN TO DESIGN MULTI-EPITOPE VACCINE AGAINST COVID-19
date: 2020-10-04
journal: Inform Med Unlocked
DOI: 10.1016/j.imu.2020.100438
sha: ff844513e36a8372df9419d172c27e943a3f1ee0
doc_id: 1049065
cord_uid: mero61ia

Stimulation and generation of T and B cell mediated long-term immune response is essential for the curbing of a deadly virus such as SAR-CoV-2. Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity screening which were linked by appropriate linkers to form a multi-epitope subunit vaccine. The physiochemical properties of the vaccine construct was analyzed and the molecular weight, molecular formula, theoretical isoelectric point value, half-life, solubility score, instability index, aliphatic index and GRAVY were predicted. The vaccine structure was constructed, refined, validated, and disulfide engineered to get the best model. Molecular binding simulation and molecular dynamics simulation were carried out to predict the stability and binding affinity of the vaccine construct with TLRs. Codon acclimatization and in silico cloning were performed to confirm the vaccine expression and potency. Results obtained indicated that this novel vaccine candidate is non-toxic, capable of initiating the immunogenic response and will not induce an allergic reaction. The highest binding energy was observed in TLR 4 (-1398.1) and the least is TLR 2 (-1479. 6). The steady rise in Th (helper) cell population with memory development was noticed and IFN-g was provoked after simulation. At this point, the vaccine candidate awaits animal trial to validate its efficacy and safety for use in the prevention of the novel COVID-19 infections.

The history of man contains a number of occasions of disease outbreaks, ranging from endemic to pandemic, which is the highest form of disease threat to humanity. According to WHO 2020, COVID-19 has led to the death of more than 431,541 persons as of June 16, 2020. Thus the mortality rate attached to COVID-19 pandemic requires a swift response, especially in the case of a new disease outbreak which demands an absolute need for new therapeutic developments [1] . Even though the curative therapeutic approach is highly clamoured for, there cannot be an effective solution to a pandemic unless preventive approach of which vaccination is a highly effective method is taken to immunize uninfected persons [2] .

The importance of immunotherapy is not unknown to the scientific community who have turned to research, to develop viable vaccines to curb the disease outbreak. Developing a vaccine for a novel virus requires explicit knowledge of the mechanism of action of the virus, also the understanding of the immune system complexities should be exploited [3] . Development of vaccine involves joint efforts of immunologists, chemical engineers and molecular biologists, who construct and create safe and efficient purified vaccines [4] .Immunization via vaccine operates based on the principle of immune system stimulation; this explicitly implies that the human body triggers its natural disease-fighting system in response to the administration of vaccine into the body [5] .

COVID-19 is a respiratory infection that is caused by a beta-coronavirus known as SARS-COV-2. It is an RNA virus, and it consists 14 receptor binding residue on it glycoprotein that interact by the angiotensin-converting enzyme 2 (ACE2) receptor [6] . This mediates the entry of the viral RNA into the host cell for infection to occur as the virus proliferate using the host cell [6] . Since the SARS-COV-2 glycoproteins (S) facilitate the viral entry into the host cell, they become the main target of antibodies. Therefore SARS-COV-2 spike glycoproteins are essential proteins for sub-unit vaccine construct. This implies that the antigenicity of the spike glycoprotein will be exploited. Thus, recognition of T-cell and B cell epitopes of the spike glycoproteins is crucial for vaccine development [7] .

Vaccination is the most efficient approach towards the prevention of infectious diseases, especially influenza, which is a highly contagious respiratory infection. Human vaccines that are licensed are mostly based on their capability to elicit humoral antibodies that block infection and possibly reduce pathogen loads [8] .

Therefore, this study proposed the design of a multi-epitope protein subunit based vaccine which is comprised of immune stimulating epitopes that can evoke humoral and cell-mediated immune response to prevent COVID-19 infection in this study.

The whole-genome nucleotide sequences were retrieved from the National Center for Biotechnology Information (NCBI) and Global Initiative on Sharing All Influenza Data (GISAID). Thirty whole-genome nucleotides were selected in GISAID from six African countries (Congo-16, South Africa -3, Senegal -7, Gambia-2, Egypt -1, Ghana -5). The whole-genome nucleotide sequences were selected based on their submission date (between March 15 and May 3, 2020) the date was picked to avoid imported cases considering community transmission (https://www.epicov.org) [9] . Five available sequences for three African countries, Nigeria -1, Tunisia -3 and South -Africa -1 as at May 5, 2020, were retrieved from NCBI. A reference sequence of an isolate from Wuhan with accession number NC_045512.2 deposited on January 17, 2020, was recovered from NCBI (https://www.ncbi.nlm.nih.gov) [10] . A total of thirty-five sequences from eight African countries were used for this study.

The retrieved African SARS-CoV-2 sequences from GISAID were annotated using the retrieved Wuhan isolate with accession number NC_045512.2 as a reference sequence using NCBI tools (https://www.ncbi.nlm.nih.gov/guide/data-software/) [11] . The whole-genome sequences were annotated to identify the position of the spike glycoprotein using pairwise alignment (https://www.ebi.ac.uk/Tools/psa/emboss needle/ ) [12] , and the aligned nucleotide sequences of the spike glycoprotein were translated to protein with protein transeq (https://www.ebi.ac.uk/Tools/st/emboss_transeq/) [13] .

The antigenicity of the spike glycoprotein was predicted using ANTIGENpro on the scratch protein (http://scratch.proteomics.ics.uci.edu/) [14] and VaxiJen (http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html) [15] . On scratch protein, sequences above the threshold of 0.8 were selected [14] , while protein sequences above the limit of 0.4 were chosen on VaxiJen [16] . The spike glycoproteins that met the criteria of at least one of the predictive analyses were further subjected to the next phase of the study.

NetCTL 1.2 server accessed through http://www.cbs.dtu.dk/services/NetCTL/ was utilized in the prediction of CTL epitopes of SARS-CoV-2 spike glycoprotein sequences that passed either ANTIGENpro (http://scratch.proteomics.ics.uci.edu/) or VaxiJen (http://www.ddgpharmfac.net/vaxijen/VaxiJen/VaxiJen.html). The MHC-1 binding peptides, Proteasomal Cterminal cleavages and Transporter Associated with Antigen Processing (TAP) transport efficiency were the three major components that the prediction was based. The threshold value used for the Epitopes identification during the CTL Epitopes prediction was 0.75 while the weights on C-terminal cleavage and TAP transport efficiency used during the prediction were 0.15 and 0.05 respectively [17] .

The HTL Epitopes on SARS COV-2 surface glycoprotein were projected using the Immune Epitope Database (IEDB) (tools.IEDB.org/mhcii/) [18] . For the Major Histocompatibility Class II (MHC II), three mouse alleles which are H2-IAb, H2-IEd and H2-IAd were selected. The predicted Epitopes were chosen by making use of their MHC-II affinity and percentile rank (which has an inverse relationship with the affinity of the epitopes predicted in the database) [19] . The six lowest scored epitopes were selected for each allele.

The linear B-cell Epitopes of SARS COV-2 surface glycoproteins were projected using B-cell Epitope prediction server; BepiPred (http://www.cbs.dtu.dk/services/BepiPred) and BCPREDS (http://ailab-projects1.ist.psu.edu:8080/bcpred/index.html). All epitopes above 0.5 thresholds (BepiPred) and justified by BCPREDS were selected and subjected to further analysis [20, 21] . In totality, eight B-cell Epitopes were chosen for the vaccine construct.

Subsequent to the predictions made above using different immuno-informatics tools, a multiepitope vaccine was built using the predicted CTL, HTL and B-Cell epitopes. The predicted epitopes for CTL and HTL were subjected to toxicity test using ToxinPred (http://crdd.osdd.net/raghava/toxinpred). RS09 motif was used as an adjuvant to improve the immunogenicity of the vaccine [22] . The CTL Epitopes were linked using AAY, while HTL and B cell epitopes were linked using GPGPG [23] .

AllerTOP (https://www.ddg-pharmfac.net/AllerTOP/) was employed in the prediction the allergenicity of the final constructed vaccine; the server uses k nearest neighbours (kNN) model with 85.3% accuracy [24] . Also, AlgPred was used to predict multi-epitope (http://www.imtech.res.in/raghava/algpred/submission.html) vaccine allergenicity with high precision, different algorithm were combined (SVMc + MAST + ARPs BLAST + IgEepitope) and exploited using AlgPred. The different approaches used can be employed in the high accuracy prediction of allergenic proteins [25] .

VaxiJen (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) was employed in the prediction of antigenicity of the vaccine; this server calculates antigenicity based on two sets of data, 100 known antigenic peptides and 100 non-antigenic peptides which were modelled with an accuracy of 70% to 89% [15, 16] . ANTIGENpro located on http://scratch.proteomics.ics.uci.edu/ is a sequenced-based, pathogen-independent and alignment-free predictor. It was also employed in the projection of the antigenicity of the vaccine construct. The antigenicity prediction was based on five machine learning algorithms and multiple representations of the primary sequence which gives result based on protein microarray data [14] .

Protparam (https://web.expasy.org/cgi-bin/protparam/) was employed in the determination of various physiochemical parameters of the constructed vaccine, the following parameters among others were accessed: molecular weight, theoretical Protrusion Index (PI), hydropathicity (GRAVY), Aliphatic index, Instability index, Extinction coefficients, Atomic Composition, Charged Residues, in vitro and in vivo half-life [26] .

J o u r n a l P r e -p r o o f

The

Self-Optimized Prediction Method (SOPMA) (https://npsa-prabi.ibcp.fr/cgibin/npsa_automat.pl?page=npsa_sopma.html) was employed for predicting the secondary structure of the vaccine construct. SOPMA predict parameters that include the helices, sheets, turns and coils [27, 28] .

I-TASSER (https://zhanglab.ccmb.med.umich.edu/I-TASSER) was used to predict the tertiary structure of the multi-epitope vaccine construct. I-TASSER tertiary structure prediction server is designed to generate a tertiary protein structure using a quantitative assessment scoring system to obtain models. The I-TASSER server gives up to five full-length output for each query. The estimated TM-score, the confidence score, the standard deviation and Root Mean Square Deviation (RMSD) of the estimations were also predicted [29] . The tertiary structure of the vaccine construct was used for the prediction of B-Cell 3D conformational structure using Ellipro (http://tools.iedb.org/ellipro), this assigned each epitope a Protrusion Index (PI). Ellipro was used to determine the conformational 3D structure of the linear B-cell epitope predicted. Jmol viewer was used in visualizing the antibody epitope predicted. The ellipro results contain the number of residue in each of the epitopes, the higher the residue, the greater its solvent availabilities [30] .

In other to refine the multi-epitope vaccine construct, Galaxy Refine web (http://galaxy.seoklab.org/cgi-bin/submit.cgi?type=REFINE) which is based on CASP 10refinement method was employed for protein side-chain reconstruction which was followed by relaxation of the structure through repacking and molecular dynamic simulation. Galaxy Refine is a proven performing algorithm for the enhancement of the quality of the local structure [31, 32] .

ProSA-web server (https://prosa.services.came.sbg.ac.at/prosa.php) is used for validation of the projected and refined 3D configuration of proteins as this is an essential step in modeling of sequences. ProSA server was employed in the validation of the 3D configuration of the vaccine construct; ProSA provided an overall magnitude of quality for the input structure. Outliers outside the characterized range of the native protein indicate a probability of occurrence of error. Ramachandran plot was also obtained by inputting the PDB file of the vaccine structure on PROCHEK server; this also validates the vaccine and authenticates this potential functionality. [33, 34, 36, 36] .

J o u r n a l P r e -p r o o f

Stimulating immune response is the target for vaccine design; this necessitates the importance of evaluating the interactions between an antigen and TLRs. ClusPro 2.0 server (http://cluspro.org/login.php?redir=/qeueue.php) was used to predict the binding pocket among TLR-2 (5d3i), TLR-3 (3ciy), TLR-4 (2z64) and TLR-9 (5zln) in the most stable complex form. Molecular docking also predicts the binding energy between the ligand and receptor by their scoring function. This was achieved by uploading the PDB file of TRLs, and the vaccine constructs onto cluspro 2.0 sever for processing and prediction [37, 38] .

Disulfide by design (http://cptweb.cpt.wayne.edu/DbD2/) was employed in the in silico process of Disulfide engineering, which provides strength to the 3D configuration of the Vaccine construct by using disulfide. The process of examining protein dynamics and interactions enhances the stability of the protein structure. Conformational entropy of unfolded protein slate is reduced due to the stability of protein after the increase. The quantification of the dynamic mobility of atoms in a protein known as B-factor is the criteria for selection [39] .

Predicting the stability of the protein-ligand complex is essential and molecular dynamics simulation is a well-accepted method to achieve this. iMOD server (http://inods.chaconlab.org) was used to carry out simulation; this approach studies the physical basis, the structure and function attributed to the biological molecules to determine the stability of the complex. This can be deduced from the result obtained as deformability, eigenvalues, and covariance [40, 41] .

In silico tool C-ImmSim (http://150.146.2.1/C-IMMSIM/index.php) was used in profiling immune response of the multi-epitope vaccine construct both humoral and cellular response against the predicted vaccine was illustrated. One shot of the vaccine product was administered. One step of simulation is equivalent to Eight hours of real time; the simulation was performed using default parameters. The volume simulated and simulation steps of 1000 was used, (random seed = 12345 with an injection of vaccine containing no LPS)

The vaccine construct was codon optimized JCAT Java tool. JCAT tool expresses protein sequences into expression systems of another biological host in order to adapt the codon for the new host, JCAT provides GC and CAI value of the adapted codon, the tool also back-translate protein sequences to DNA sequences which are further used in silico cloning. In this study, JCAT was used to adjust the final vaccine sequences into the E. coli K12 strain expression system by inputting the construct of the final vaccine which is processed for adaptation [42] . DNA sequences obtained from back-translation was cloned into the E. coli K12 pET-28a(+) vector expression system at specific restriction enzymes with the aid of SnapGene software [43] .

The antigenicity of spike glycoprotein annotated from each of the sequences was predicted, and 25.7% of the sequences passed AntigenPRO at a threshold 0.8 while 100% of the selected available sequences passed VaxiJen at a threshold of 0.4. The sequences that passed were then subjected to further analysis.

CTL, HTL and B-cell epitopes were projected using a different server with the selected glycoprotein sequences that passed antigenicity screening. 9 CTL with 9-mer was predicted based on their high score, which was within the threshold of 0.75 (Table 1a) . T Helper Lymphocytes epitopes were also predicted; those with low percentile rank were selected (Table  1b) . B-Cell epitopes within the threshold of 0.5 were selected (Table 1c ) and used in vaccine construction along with the HTL and CTL.

A multi-epitope vaccine was constructed from the predicted CTL, HTL and B-cell binding epitopes, linkers were employed in the linking of the epitopes and an adjuvant was linked to the construct to aid the potency of the vaccine. AAY was used to link CTL together, GPGPG was used to connect HTL and B-cells, and EAAK was used to link the adjuvant [22] to the whole construct. This construct is the final vaccine construct (Fig.1 ).

The final vaccine construct was subjected to allergenicity, antigenicity and toxicity screening; the vaccine was non-allergenic as reported on the AllerTOP and Algpred server, VaxiJen 2.0 and ANTIGENpro predicted that the vaccine could elicit an antigenic reaction and tonxinPred predicted its non-toxicity. A comparative analysis of the epitopes in the vaccine with the human proteome was done using BLASTp server, which shows that no significant similarity exists between the vaccine and human proteome.

J o u r n a l P r e -p r o o f Physiochemical analysis done on protparam showed that the molecular weight of the construct was73253.02. The construct has a molecular formula of C 3330 H 4905 N 895 O 952 S 17 ; the theoretical isoelectric point value was predicted at 9.22. The half-life was predicted to be 4.4 hours in mammalian reticulocytes in vitro, >20 hours for yeast and >10 hours in E. coli. Instability index (II) was 25.82; aliphatic index prediction was 56.60. The GRAVY was at-0.425. Alanine, Glycine and serine were observed to be in abundant.

SOPMA online server was utilized in the prediction of the secondary structure of the constructed vaccine. The server provided in addition to the secondary structure information on the vaccine construct, which include, Alpha helix 15.75%, extended strand 19.35%, Random coil 63.29% and Beta turn structure 2.60%. These were all represented in Figure 2 . The high percentage of the random coil, as seen from the figure, indicates the high concentration of epitope at that point [44] .

I-TASSER (https://zhanglab.ccmb.med.umich.edu/I-TASSER) was employed in predicting the 3D configuration of the multi-epitope vaccine construct. Five models were predicted, but model 1 was chosen based on the confidence score of -2.14, the estimated TM-score, 0.46±0.15 and Root Mean Square Deviation (RMSD) at 13.3 ±4.1 Å. The B-cell conformational epitope for the vaccine construct was identified using Ellipro server (Fig 4.) 

Refinement of the 3D configuration involves reconstruction of side chains of the protein, molecular dynamic simulation and repacking; this is to relax the tertiary structure of the vaccine. Galaxy Refine webserver was employed to refine the configuration of the vaccine, five refined models were predicted, and model 1 was selected on the criteria which include 0.9187 GDT-HA, 0.501 RMSD, 2.814 MolProbity, Clash score of 38.1, Poor rotamers of 1.1, Rama favoured 82.0.

The Ramachandran map showed ( Figure 5 ) distribution for the protein model for which 83.3% was in the favoured region, 11.3% in the allowed area and 5.4% found in the disallowed region. ProSA web predicted a Z-score of -1.46 for the inputted vaccine model; this is lying outside the score range that is frequently found in the case of native proteins of comparable size and ERRAT online server revealed a quality score of 68.64%.

Disulfide engineering was done via the disulfide by Design v2.0 server; this is necessary to enhance and aid the stability of the structure of the refined vaccine. A total of 98 pair of residue J o u r n a l P r e -p r o o f useful for disulfide engineering was found from which ten pair (PRO511-SER532 ARG574-TYR577 ARG48-GLY77 ASP587-TYR602 SER597-SER601 VAL106-GLY543 ALA593-ARG598 PRO168-GLU566 GLY51-ASN514 MET64-ARG69) were selected on the ground of their energy, Chi3 value and high B-factor as shown in Figure 6 .

Docking is the in silico process of simulating the binding of the vaccine with TLRs to predict how the vaccine would bind to TLRs In vivo. Molecular docking for this vaccine was done using ClusPro 2.0, TLR2, TLR3, TLR4 and TLR9 were used individually as the receptor (Figure 7) . The projection of Molecular interaction of the vaccine with the receptors generated models from which the best were selected for each receptor-ligand complex based on their binding energy weight as indicated in Table 2 .

Normal Model Analysis (NMA) for the selected docked vaccine-receptor complex was carried out to study the stability and mobility employing the iMODs server. The vaccine protein and its receptor were predicted to spin towards each other; the relationship is represented by small black arrows as shown in figure 8a, 9a, 10a and 11a for TLR2, TLR3, TLR4 and TLR9, respectively. The hinges in the high deformability region indicate the deformability of the vaccine-receptor complex as shown in figure 8e, 9e, 10e and 11e for TLR2, TLR3, TLR4 and TLR9 respectively. The B-factor is directly proportional to the value of RMS as inferred through NMA (fig 8d, 9d,  10d, and 11d) . Eigenvalue for the vaccine-receptor complexes as obtained from iMODs server were 2.27e-05, 2.06e-06 and 1.53e-05 for TLR2, TLR3, TLR4 and TLR9 respectively (Fig. 8c,  9c, 10c and 11c) . Variance is reported to be inversely proportional to the Eigen's value. The graphs of the variance can be seen from figure 8g, 9g, 10g, and 11g for TLR2, TLR3, TLR4 and TLR9 respectively. From the graphs of the residual index, the colour codes red, blue and white represent the correlated, anti-correlated and uncorrelated pairs of residues in the variance matrix ( fig. 8b 9b, 10b and 11b) . The map was observed to be different for each of the vaccine-TLR docking. The elastic network model generated by iMODs ( fig. 8f, 9f, 10f and 11f) represents the pair of atoms connected via springs. Each dot represents one spring between the corresponding pairs of atoms; stiffer springs are represented by the dark grey areas in the elastic graph.

The integration of COVID-19 vaccine construct into the E. coli expression system requires the use of JCAT and SnapGene server. Adapting the vaccine into E. coli k12 strain predicted a GC content of 57.03%, Codon Adaptation Index (CAI) of 0.92 and back-translate the protein sequence to an E. coli codon compatible nucleotide. The back-translated nucleotide was adapted into the expression system of E. coli using restriction enzyme XhoI (158) and XbaI (335) as a cloning site (Fig 12) .

The C-ImmSim server (http://150.146.2.1/C-IMMSIM/index.php) revealed the system of successful immune response and the increased half-life of the vaccine candidate. The specific immunoglobulin and interleukin concentrate was shown (fig 13a & c) . Activity of the CD4, Thelper lymphocytes count (fig 13b) as well as B lymphocytes count was uncovered.

The recent outbreak of the COVID-19 pandemic placed the world in a state of emergency, that resulted in the need for solution against the viral scourge by the world of science and research. It is a well-known fact that prevention is far better than cure, this can never be over-emphasized hence it demands quick response of scientist all over the world.

Vaccine is known as the surest way to prevent the spread of infectious diseases. Immunoinformatics has made vaccine development possible in a shorter period of time and subunit vaccines which is a type of vaccine derived from fragment of whole genome of the organism having the ability to induce humoral and cellular mediated response, without reverting to wide type strain and eliminating the risk of pathogen handling has impacted positively the vaccine design and development as Fauci once said "the global need for a vaccine and the wide geographical diversity of the pandemic require more than one effective vaccine approach." For this study, amino acid sequence of SARS-CoV-2 spike glycoproteins were gotten from NCBI and GISAID. SARS-CoV-2 spike glycoproteins were selected based on the report that they possess receptor binding domain (RBD) which is specific to ACE-II receptor, this mediates viral entry into the host. Spike glycoproteins are also known to be antigenic with relatively conserved protein residue [6] hence, making it a good target for inducing immunogenic response.

The selected sequences were subjected to antigenic and allergenic screening and were found to be antigenic and non-allergenic; which is a crucial aspect of vaccinology. CTL, HTL and B-Cell epitope prediction was carried out because multi-epitope vaccine requires CTL, HTL and B-Cell epitopes [45] . This is important since T-cells recognize the surface antigen presented by the MHC molecules. MHC class II molecules present surface antigen to T-helper cells and B-cell;

recognize and bind to B-cell epitopes to elicit antibody and memory cells. The result obtained J o u r n a l P r e -p r o o f from these analyses revealed the spike glycoproteins comprise a large quantity of MHC-II and Bcell binding epitope; these were employed in building the vaccine candidate using appropriate linkers. Vaccine requires an adjuvant for a robust immune response, attaching an adjuvant to a vaccine implies a linker was also used; hence the complete vaccine construct.

Understanding the physiochemistry of a vaccine is necessary in order to estimate its stability, solubility and other physical properties of the protein in vitro and in vivo, the properties as predicted by the physiochemical predicting server (protparam) suggests that the vaccine has a molecular weight of 73.5 kDa, this is within the range for an accepted vaccine candidate [26] , theoretical pI value of 9.22 showed a basic vaccine depicting a good structural fold, the aliphatic index was predicted at a score of 56.60 showing that the vaccine has aliphatic side chains, the instability index (25.82) predict the vaccine to be stable. The hydrophobicity of the vaccine was revealed by the GRAVY result of -0.425. The half-live was predicted to be 4.4 hours in mammalian reticulocyte in vitro, >20 hours inside yeast and 10 hours in E. coli in vivo.

The tertiary structure of the vaccine candidate was predicted using I-TASSER server and the best structure was selected based on its high c-score (-2.14). Tertiary structure prediction provided information that includes TM-score (0.46±0.15) and RMSD at 13.3 ±4.1 Å, the arrangement of the residue that are important in the protein study of the vaccine was also provided. The structure was further used for various studies which include, molecular docking for receptor-ligand relationship, dynamics study which at the microscopic level gives an insight of the stability of the receptor-ligand complex, and disulfide prediction for vaccine stability that helps in analyzing how the vaccine will react when the vaccine is exposed to biochemical stress within the host system as earlier described by Pandey et al. [46] .

Structural prediction expresses the structure of vaccine candidate but the structure requires refinement and validation [34] . Performing refinement provides a refined 3D vaccine model Pattern-recognition receptors (PRRs) are means by which the immune system recognizes pathogen-associated molecular pattern (PAMPs). Vertebrate host encompasses different class of PRRs such as RIG-I-like receptor (RLRs), C-type lectin receptor, NOD-like receptor and Tolllike receptors (TLRs) [47] . TLRs ligands activate the maturation of dendritic cells and consequently activate their ability to trigger adaptive immune responses and in effect, tag antigens as pathogenic. Another significance of TLR-induced DC maturation is the amplification of a variety of cytokines and chemokines [47] . Malcolm et al. [48] pointed out that TLR signaling is a fundamental link between innate and adaptive immunity, TLRs expression varies among different host cell. Several TLRs have been associated in antiviral immunity, TLR 2 are responsible for recognition of structural and non-structural viral protein which induce inflammatory cytokine production, TLR 2, 3, 4 and 9 identify specific forms of viral nucleic acids and are sacrosanct in recognizing viral genetic materials in endolysosomal compartment hence responsible for antiviral signaling [49] .

The binding energy and molecular relatioship of the multi-epitope subunit vaccine with TLR (2, 3, 4 and 9) was probed by molecular docking. One model was selected from each of the docked complex on the basis of their proper receptor interactions, low binding energy and center energy scores [50] . Their Van Der Waals interactions, partial electrostatics and hydrophobic-favour was also considered ( Table 2) . Dynamics result showed a positive eigenvalue (2.27e-05; 2.06e-06; 2.03e-05; 1.53e-05) which is significant in the vaccine and rotation of the constructed vaccine which has been reported from several studies [51, 52, 53] .

How soluble the over expressed recombinant protein in the E. coli host occur is critical for many biochemical and functional investigations, thus adapting the vaccine model into an E. coli expression system is an essential step in vaccine design and codon adaptation is one of the preferred ways to express the rate of foreign genes in a host, this is because when the codon used by the host differs from that of the organisms gene, minor expression rate may occur when the genes are not adapted. Therefore we adapted the final vaccine protein sequences to E. coli strain K12 utilizing JCAT server and obtained results that was satisfactory. JCAT also back-translated the protein sequences to nucleotides, the nucleotide was cloned into E. coli pET28a(+) vector J o u r n a l P r e -p r o o f XhoI and XbaI restriction sites, the total length of the clone was 7.2Kbp and is represented in red. The target sequence was encoded between 6-histidine residues, this would prove useful in purification purpose.

The memory of the immune cells patterned by a mechanism that increases cell half-life and successful immune response is reflected by C-ImmSim. The pathway enables some cells to live longer than others by increasing their half-life . The primary response is designated by IgM, and the antigen clearance is a result of immunoglobulins secretion; a property of an increased B-cell population. The steady rise in Th (helper) cell population with memory development was noticed and IFN-g was provoked after simulation (Figure 13a-d) . B cells and T cells population were highly reactive with consistency in other immune cells. The IFN-g which is capable of inducing and modulating an array of immune response that was observed in this study, is different from the IFN-c reported by Peele et al. [54] . Also the difference in data output could be due to administration of successive dose at intervals compared to the single dose administered in our study. However, it was observed that the B cell lymphocyte curve was maintained with time (which is an indication of a stable/prolonged half-life and invariably the efficacy of the vaccine prototype within the host cell with time), contrary to the curve in the report of Peele et al. [54] .

Transforming growth factor (TGF) is responsible for sustaining tolerance against self and mild antigen and in controlling immune responses to pathogen. Interleukin (IL 2, 4, 10 & 12) maintains the propagation, enhancement of cytotoxicity, IFN-g secretion, and antibody production; Immune suppression, decreases antigen presentation and MHC class II expression of dendritic cells, down-regulates pathogenic Th (1, 2, 17) responses. IL (4&10) has specific antiinflammatory properties by suppressing the expression of inflammatory cytokines. IL12 stimulates cytokine secretion and boosts cytotoxic activity enhancing T and NK cells for IFN-g production which promotes Th1 differentiation and plays functional interaction between the innate and adaptive immunity [55] . Immune simulation results authenticates consistency with actual immune responses.

Eradicating SARS-COV-2 will be unachievable unless novel control methods are implemented among which vaccine should be taking as very important because the number of infected people are still very few compared to the uninfected at the risk of being infected due to the high rate of J o u r n a l P r e -p r o o f transmission resulting from it being extremely contagious. In this research, immunoinformatics approach was employed to construct a potential vaccine using the spike glycoproteins coding for multiple T-cell (HTL and CTL) and B-cell epitopes. The vaccine peptide has potential to confer prophylactic benefits. Howbeit, this a priori computational work requires experimental validation to substantiate this study, and this may include the development of the designed subunit vaccine followed by in vitro and in vivo study to establish the immunogenicity and safety of potential vaccine. J o u r n a l P r e -p r o o f 

Coronavirus disease 2019 (COVID-19) situation report-147

International travel and health Chapter 6: Vaccinepreventable diseases and vaccines

Leishmania-host-cell interaction: complexities and alternative views

Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach

Biology of C Reactive Protein in Health and Disease 1-32

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Improved method for predicting linear B-cell epitopes

Histocompatibility Complex Class II in Inducing Protective Immune Responses to Influenza Vaccination

GISAID: Global initiative on sharing all influenza datafrom vision to reality

Database resources of the national center for biotechnology information

The NCBI

Evolution of Klebsiellapneumoniae with mucoid and non-mucoid type colonies within a single patient

Computational prediction and analysis of envelop glycoprotein epitopes of DENV-2 and DENV-3 Pakistani isolates: a first step towards Dengue vaccine development

High-throughput prediction of protein antigenicity using protein microarray data

Analysis of the DosRregulon genes to select cytotoxic T lymphocyte epitope specific vaccine candidates using a reverse vaccinology approach

VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines

In silico identification of cytotoxic T lymphocyte epitopes encoded by RD5 region of Mycobacterium tuberculosis

The immune epitope database (IEDB) 3.0

A Bayesian regression approach to the prediction of MHC-II binding affinity

BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes

Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes

Encryption of agonistic motifs for TLR4 into artificial antigens augmented the maturation of antigen-presenting cells

Development of multi-epitope driven subunit vaccine against Fasciolagigantica using immunoinformatics approach

AllerTOP v. 2-a server for in silico prediction of allergens

AlgPred: prediction of allergenic proteins and mapping of IgE epitopes

SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments

The conserved proline residue in the LOB domain of LBD18 is critical for DNA-binding and biological function

I-TASSER server for protein 3D structure prediction

ElliPro: a new structure-based tool for the prediction of antibody epitopes

GalaxyRefine: protein structure refinement driven by side-chain repacking

GalaxyWEB server for protein structure prediction and refinement

PROCHECK: validation of protein-structure coordinates

ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins

Recognition of errors in the refinement and validation of three-dimensional structures of AC1 proteins of begomovirus strains by using ProSA-Web

Cloning, characterization and bioinformatics analysis of novel cytosine deaminase from Escherichia coli AGH09

ClusPro-DC: Dimer classification by the CLUSPRO server for protein-protein docking

The ClusPro web server for protein-protein docking

Disulfide by Design 2.0: a web-based tool for disulfide engineering in proteins

iMODS: internal coordinates normal mode analysis server

Design, Development, and Implementation of the Instructional Module Development System (IMODs)

JCat: a novel tool to adapt codon usage of a target gene to its potential expression host

Characterization of the novel T4-like Salmonella enterica bacteriophage STP4-a and its endolysin

In Silico Prediction of B-Cell and T-Cell Epitopes of Protective Antigen of Bacillus anthracis in Development of Vaccines Against Anthrax

Designing a multi-epitope based vaccine to combat Kaposi Sarcoma utilizing immunoinformatics approach

Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection

Toll-Like Receptors: Linking Innate and Adaptive Immunity

Use of defined TLR ligands as adjuvants within human vaccines

Toll-like receptors in antiviral innate immunity

Novel immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein

Contriving a chimeric polyvalent vaccine to prevent infections caused by herpes simplex virus (type-1 and type-2): an exploratory immunoinformatic approach

Immuno-informatics approach to design a multiepitope vaccine to combat cytomegalovirus infection

Exploiting the reverse vaccinology approach to design novel subunit vaccines against Ebola virus

Design of Multi-Epitope Vaccine Candidate Against SARS-COV-2: A In-Silico Study

Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

The authors would like to acknowledge Helix Biogen Consult, Ogbomoso and TrimLabs, Ogbomoso, Oyo State, Nigeria for resources and technical support. We would also like to appreciate Odeyemi Ayodeji Emmanuel and Akintola Deborah Adenike for their significant contribution towards the success of this study.

J o u r n a l P r e -p r o o f There is no conflict of interest